PT ESA MEDIKA MANDIRI Tbk

PT Esa Medika Mandiri Tbk Reaffirms Commitment to Sustainable Growth in Its First Financial Report as a Listed Company

31 July 2026 – PT Esa Medika Mandiri Tbk (EMMI), an Indonesian medical device manufacturer, today announced its consolidated interim financial results for the six-month period ended 30 June 2026. This marks the Company's first financial report following its successful listing on the Indonesia Stock Exchange (IDX) on 8 July 2026.

The release of this inaugural financial report represents an important milestone in EMMI's journey as a public company and underscores its commitment to upholding transparency, sound corporate governance, accountability, long-term value creation for shareholders and stakeholders, and company Good Corporate Governance.

Net sales increased more than fourfold to **IDR 65.35 billion**, from **IDR 15.40 billion** in the first half of 2025. Gross profit also rose substantially to **IDR 26.15 billion**, compared with **IDR 7.34 billion** in the corresponding period last year. Meanwhile, net loss narrowed by approximately **32% year-on-year**, reflecting continued improvements in the Company's operational fundamentals.

Strong Operational Improvement in the First Half of 2026

During the first half of 2026, the Company delivered significant improvements in its operating performance compared with the same period last year.

Net sales increased more than fourfold to **IDR 65.35 billion**, from **IDR 15.40 billion** in the first half of 2025. Gross profit also rose substantially to **IDR 26.15 billion**, compared with **IDR 7.34 billion** in the corresponding period last year. Meanwhile, net loss narrowed by approximately **32% year-on-year**, reflecting continued improvements in the Company's operational fundamentals.

First Half Performance Reflects Industry Procurement Cycle

Management noted that the medical device industry, particularly its government healthcare institution segment, is characterized by procurement activities that are typically concentrated in the second half of the year, in line with government budget realization and the completion of tender processes. Consequently, revenue and earnings generated during the first half do not fully reflect the Company's business activities throughout the financial year.

Accordingly, the first half of the year has primarily been focused on strengthening the Company's business fundamentals through disciplined operational management, inventory readiness, supply

ESA 8 Building, 10th Floor • Jl. Ir. Soekarno Kavling 3-5 • Paramount, Gading Serpong • Tangerang, Banten 15332 • INDONESIA
Telp. : (62-21) 39702800, 50898800 (Hunting) • Email : ptesa@esamedika.com • www.esamedikamandiri.com

chain optimization, and participation in various government procurement tenders, the outcomes of which are expected to materialize during the second half of 2026.

Beyond the public sector, the Company continues to strengthen its presence in the private hospital segment and other healthcare facilities to support sustainable business growth throughout the year.

Positive Outlook for the Second Half of 2026

Management remains positive on the Company's business outlook for the second half of 2026.

EMMI currently has several projects scheduled for execution during the remainder of the year and is participating in a number of government procurement tenders that are currently under evaluation.

As procurement activities accelerate in the second half, the Company believes this will provide continued momentum for revenue growth through year-end.

As a newly listed company, EMMI views its IPO not merely as a fundraising exercise, but as the beginning of a new phase of corporate growth. IPO proceeds are being utilized progressively in accordance with the use of proceeds disclosed in the Prospectus to support manufacturing expansion, strengthen competitiveness, and reinforce the Company's long-term growth foundation.

The Company also continues to enhance its corporate governance framework, risk management practices, and prudent financial management as part of its commitment to building a resilient, adaptive, and sustainable business capable of delivering long-term value for all stakeholders.

IPO Proceeds Utilization Progressing as Planned

In line with the strategic initiatives disclosed during its Initial Public Offering (IPO), the Company continues to develop its new manufacturing facility in Cikupa.

Construction is progressing according to plan and is expected to further strengthen EMMI's domestic manufacturing capabilities, enhance its ability to meet Indonesia's growing demand for medical devices, and support higher Domestic Component Level (TKDN) compliance across its product portfolio. Management believes the disciplined execution of the IPO proceeds will further strengthen the Company's business fundamentals and position EMMI to capture long-term growth opportunities in Indonesia's medical device industry.

Beyond expanding its production capacity, EMMI is also laying the foundation for future international growth. This commitment was further demonstrated through the visit of a delegation

ESA 8 Building, 10th Floor • Jl. Ir. Soekarno Kavling 3-5 • Paramount, Gading Serpong • Tangerang, Banten 15332 • INDONESIA
Telp. : (62-21) 39702800, 50898800 (Hunting) • Email : ptesa@esamedika.com • www.esamedikamandiri.com

from Indonesia's Ministry of Foreign Affairs to the Company's manufacturing facility on 29 July 2026. The visit provided an opportunity to showcase EMMI's manufacturing capabilities and export readiness, while consistent with the Company's long-term strategy to strengthen its manufacturing capabilities and build readiness for international markets. The Company believes such collaboration will further enhance the global competitiveness of locally manufactured medical devices and create broader opportunities for Indonesian healthcare products in international markets.

Management Commentary

Florian Chris Widjaja, President Director of PT Esa Medika Mandiri Tbk, commented, "This first-half financial report represents our inaugural financial reporting as a listed company. We are pleased to have delivered strong revenue growth compared with the previous year while continuing to improve the Company's operational performance. Although the first half remains affected by the seasonal procurement cycle, particularly among government healthcare institutions where procurement activities are generally concentrated in the second half of the year, the underlying business indicators continue to progress in line with our expectations."

He added, "The Company currently has several projects scheduled for execution during the second half, alongside a number of government procurement tenders that remain under evaluation. Supported by our project pipeline, we are confident in sustaining our growth momentum through the remainder of the year. At the same time, as a public company, we remain committed to deploying our IPO proceeds in accordance with the Prospectus to strengthen manufacturing capacity, enhance corporate governance, and reinforce our long-term competitiveness."

2026 Outlook

Supported by increasing procurement activity in the second half, a healthy project pipeline, and the continued execution of its post-IPO strategy, EMMI remains optimistic about sustaining its growth trajectory throughout the remainder of 2026, despite ongoing macroeconomic challenges.

The Company will also continue to strengthen its contribution to Indonesia's medical device industry through expanded manufacturing capacity, product innovation, and stronger collaboration with healthcare institutions, industry associations, and government agencies. These partnerships are expected to support EMMI's growth in both domestic and international markets, in line with management's long-term aspiration to establish the Company as a competitive Indonesian medical device player on the global stage.

PT ESA MEDIKA MANDIRI Tbk

About PT Esa Medika Mandiri Tbk

PT Esa Medika Mandiri Tbk is an Indonesian medical device company established on 26 January 2000 and headquartered in Tangerang, Indonesia. The Company specializes in the manufacturing and distribution of operating room and intensive care unit (ICU) medical products, serving healthcare institutions across the country.

For further information:
Corporate Secretary
PT Esa Medika Mandiri Tbk
Email: corpsec@esamedika.com
Website: https://esamedika.com/